Could a Once-Daily pill prevent deadly clots in cancer patients?
NCT ID NCT07005024
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two different dosing schedules of the blood thinner apixaban (Eliquis) against no blood thinner in about 996 cancer patients at moderate risk for blood clots. Participants take either 2.5 mg twice daily, 5 mg once daily, or no anticoagulant for 6 months. The goal is to see if a simpler once-daily dose is as safe and effective as the standard twice-daily dose at preventing clots and reducing deaths.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Apixaban (Eliquis), a blood thinner
- What this could lead to
- If successful, this could provide a simpler, once-daily blood thinner option to prevent dangerous clots in cancer patients, potentially reducing deaths and hospitalizations.
- What could go wrong
- This is a Phase 3 trial, but it's still testing a new dosing schedule. The once-daily dose may not work as well as the standard twice-daily dose, and any blood thinner carries a risk of serious bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Vermont Medical Center
RECRUITINGBurlington, Vermont, 05401, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could muscle loss predict blood cancer outcomes?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare